Roisin Delaney

  • Research

    Roisin Delaney will be researching the regulation of Ras signaling for cancer therapy.

  • Biography

    Roisin received her M.Pharm degree from the University College London School of Pharmacy.

Publications

 

View All Publications

Roisin Delaney's Research Focus

RAS is a critical oncogene in many cancers for which there is no effective therapy. Ras activates downstream effectors as part of a signaling nanocluster in association with other proteins. These may form surrogate targets for attacking KRas for therapy. Roisin Delaney will be researching the regulation of Ras signaling for cancer therapy. In specific, she will investigate the role of the signaling nanocluster PH domain protein CNKSRI in KRAS activity, how the PLEKHA7 PH protein interacts with CNKSRI to regulate KRAS activity and the role of PH domain binding agents as inhibitors of mutant KRAS signaling and cancer cell growth.

About Roisin Delaney

Experience

Roisin received her M.Pharm degree from the University College London School of Pharmacy. She undertook research for her masters dissertation in the department of Experimental Therapeutics at MD Anderson Cancer Center in Houston. She entered the graduate program in 2013.

Become a Partner / Donate
Your support is crucial in turning hope into healing. Your support is crucial in turning hope into healing. Learn More
Sign In Skip Navigation Links Skip navigation links
Our Mission
Research
Talent
Technology
Training & Education
Our Supporters
Privacy Policy